门冬胰岛素(Insulin aspart) - 药物靶点：INSR_在研适应症：2型糖尿病，糖尿病_专利_临床

概要

基本信息

药物类型

激素

别名

Insulin Aspart (Genetical Recombination)、Insulin Aspart 30、Insulin Aspart 50

+ [17]

靶点

INSR

作用机制

INSR激动剂(胰岛素受体激动剂)

治疗领域

内分泌与代谢疾病

在研适应症

2型糖尿病糖尿病

非在研适应症

急性淋巴细胞白血病淋巴母细胞淋巴瘤伯基特淋巴瘤+ [7]

原研机构

Novo Nordisk A/S

在研机构

Novo Nordisk, Inc.Novo Nordisk Pharmaceuticals Pty Ltd.

Novo Nordisk A/S

非在研机构

诺和诺德（中国）制药有限公司

Mylan, Inc.

最高研发阶段批准上市

首次获批日期

欧盟 (1999-09-07),

糖尿病

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

序列信息

Sequence Code 4857

来源: *****

Sequence Code 31953

来源: *****

关联

242

项与门冬胰岛素相关的临床试验

NCT06547619 / Recruiting早期临床1期

Role of ET-1, Physical Activity, and Sedentary Behavior in Microvascular Dysfunction Following GDM

Women with a history of gestational diabetes mellitus (GDM) are at a 2-fold greater risk for the development of overt cardiovascular disease (CVD) following the effected pregnancy. While subsequent development of type II diabetes elevates this risk, prior GDM is an independent risk factor for CVD morbidity, particularly, within the first decade postpartum. GDM is associated with impaired endothelial function during pregnancy and decrements in macro- and microvascular function persist postpartum, despite the remission of insulin resistance following delivery. Collectively, while the association between GDM and elevated lifetime CVD risk is clear, and available evidence demonstrates a link between GDM and vascular dysfunction in the decade following pregnancy, the mechanisms mediating this persistent dysfunction remain unexamined.
The purpose of this investigation is to examine the role of endothelin-1, a potent vasoconstrictor, in aberrant microvascular function in otherwise healthy women with a history of GDM and to identify whether this mechanism is influenced by physical activity and sedentary behavior.

开始日期2024-10-01

申办/合作机构

University of Iowa

NCT06532461 / RecruitingN/AIIT

A Randomized Controlled Trial Testing the Influence of Three- and Seven-days Insulin Infusions and Two Types of Insulin on Hyperechogenicity in Subcutis and Glycemic Variables in Children and Adolescents With Type 1 Diabetes

More and more children and adolescents are using diabetes devices attached to the skin. The attachment of infusions sets to the skin provoke allergenic or toxic eczema, the continous infusion of insulin provoke subcutaneous changes and prolonged wear time seems to increase the risk of these complication. On the other site fewer skin stripping episodes with longer wear time and filtration of the insulin may be beneficial for the skin, therefore comparing the occurrence of subcutaneous hyper echogenicity, eczema and the skin barrier in users of 3 and 7 days infusions set is highly relevant. The primary aim of present study is to investigate if the use of three days insulin infusion set is superior to seven days in preventing the occurrence of hyperechogenicity in areas recently used for insulin infusion and if the type of insulin matter comparing insulin aspart - Novo Rapid, or insulin lispro - Humalog

开始日期2024-07-20

申办/合作机构

Steno Diabetes Center A/S

NCT06558708 / Recruiting临床2期

A Phase II Trial Comparing Efficacy, Tolerability, and Safety of GZR101 Injection and GZR33-70 Injection in Type 2 Diabetes Inadequately Controlled on Basal Insulin or Premixed Insulin Once Daily at Least With or Without Pre-dinner Meal-time Insulin

This trial is conducted in China. The aim of the trial is to compare the efficacy, tolerability, and safety of GZR101 Injection and GZR33-70 Injection in type 2 diabetes inadequately controlled on basal/ premixed insulin once daily at least with or without pre-dinner meal-time insulin.

开始日期2024-06-28

申办/合作机构

甘李药业股份有限公司

100 项与门冬胰岛素相关的临床结果

登录后查看更多信息

100 项与门冬胰岛素相关的转化医学

登录后查看更多信息

100 项与门冬胰岛素相关的专利（医药）

登录后查看更多信息

1,395

项与门冬胰岛素相关的文献（医药）

2024-12-02·ChemMedChem

Higher Order Structure Differences Among Insulin Crystalline Drugs Revealed by 2D heteronuclear NMR

Article

作者: Rienstra, Chad M. ; Wang, Songlin ; Chen, Kang

Abstract:

During therapeutic protein development, two‐dimensional (2D) heteronuclear NMR spectra can be a powerful analytical method for measuring protein higher order structure (HOS) in solution since the spectra exhibit much higher resolution than homonuclear 1H spectra. However, 2D NMR capabilities for characterizing protein HOS in crystalline states remain to be assessed, given the low 13C natural abundance and intrinsically broader lines in solid‐state NMR (SSNMR). Herein, high‐resolution heteronuclear correlation (HETCOR) SSNMR was utilized to directly measure intact crystal drug products of insulin human, insulin analogs of insulin lispro and insulin aspart. The fingerprint regions in 2D 1H−13C HETCOR spectra were identified, which distinguished the insulin crystals in their primary structure, HOS heterogeneity and dynamics, as well as the manufacturing processes. The HOS heterogeneity in insulin analogs is consistent with their therapeutic effect of rapid action; while insulin human crystals showed more structural homogeneity, consistent with their slower pharmacokinetics (PK) peak time than insulin analogs. Therefore, heteronuclear NMR could be broadly applicable to study protein drug dosage forms from liquid to solid, yielding improved molecular level structure data for assessing drug HOS in biosimilar drug development.

2024-12-01·Diabetes Therapy

Switching from Premixed Insulin to Insulin Degludec/Insulin Aspart for the Management of Type 2 Diabetes Mellitus: Implications of a Real-World Study on Insulin Degludec Dosing

Article

作者: Wu, Yiming ; Li, Ang ; Zhang, Junqing

INTRODUCTION:

When switching from premixed insulin to insulin degludec/aspart (IDegAsp), IDegAsp usually starts at the same dose as the premixed insulin according to limited clinical experience or at a dose according to clinician discretion. The dose of insulin degludec used in the real world after switching has been poorly investigated.

METHODS:

A retrospective analysis was conducted on patients with type 2 diabetes who switched from premixed insulin to IDegAsp from October 2016 to December 2023. Repeated measures analysis of variance was used to compare changes in insulin dose, glycated hemoglobin (HbA1c), fasting blood glucose (FBG), and postprandial blood glucose (PBG) before and after switching.

RESULTS:

Sixty-six patients with prior low-ratio premixed insulin and 22 with prior mid-ratio premixed insulin were included. Among the low-ratio insulin users, the total daily dose of insulin degludec (IDeg) decreased by 21.43% and 19.05% at 3 and 6 months, respectively, after switching, compared with prior basal insulin dose (both p < 0.001). Conversely, among mid-ratio insulin users, the IDeg daily dose increased by 10.71% and 32.14% at 3 and 6 months, respectively, after switching, compared with prior basal insulin dose (both p < 0.001). In all patients, HbA1c levels decreased by 0.70%, FBG decreased by 1.00 mmol/l, and PBG decreased by 1.61 mmol/l after 6 months of switching (all p < 0.05); the total daily insulin dose and injection frequency significantly decreased after switching (both p < 0.05); age and disease duration did not affect IDegAsp effects on HbA1c reduction.

CONCLUSIONS:

In the setting of transition to IDegAsp from premixed insulin, the dose of basal insulin in the premixed formulation can be a valuable reference for adjusting insulin degludec dose. IDegAsp is superior to premixed insulin in blood glucose control with reduced total daily dose and injection frequency. IDegAsp could be the best choice for the management of diabetes in elderly patients.

2024-12-01·Fresenius Zeitschrift für Analytische Chemie

Analysis of multi-disulfide bridges for insulin aspart by stepwise reduction and differentiated alkylation

Article

作者: Meng, Xiaoguang ; Lin, Ling ; Yao, Huan ; Li, Ming ; Hu, Zhishang ; Wu, Peize ; Cui, Xinling

Disulfide bridge, an important post-translation modification in protein, plays a key role in stabilizing three-dimensional structure of proteins, maintaining correct folded conformation, and thus regulating the biological activities. Disulfide bridge assignment is essential to understand the essence of life process and to develop protein pharmaceutical. In this study, a novel method termed as stepwise reduction and differentiated alkylation (SRDA) was developed analyzing disulfide connectivity for proteins. As a demonstration, three disulfide bridges in insulin aspart were successfully characterized using this SRDA method combined with LC-HRMSⁿ. Firstly, tris (2-carboxyethyl) phosphine (TCEP) was used to partially reduce disulfide bridges with N-ethylmaleimide (NEM) used to block the generated free thiol. Then, dithiothreitol (DTT) was used to reduce the rest disulfide bonds with iodoacetamide (IAM) used to block the newly generated free thiol. After that, an LC-HRMSⁿ method was established to assign disulfide connectivity for an insulin aspart study material, based on the different mass shifts arising from differentiated alkylation. Moreover, this approach allows for the quantitative analysis of various disulfide bond pairings, which can be applied to studies on the consistency and stability among different batches of samples. The results show that SRDA is a valuable tool for reliable quality control and quality assessment of disulfide-rich proteins such as insulin analogues.

180

项与门冬胰岛素相关的新闻（医药）

2024-12-10

·医药健闻

药明康德2000万欧元出资法国医疗投资机构；恒瑞医药拟在港交所主板上市；诺和165亿美元收购案获欧盟无条件批准 | 日报

全球医疗行业每日重点资讯文 | 苏丁企业动态罗氏（Roche）宣布将投资超过6亿欧元，在德国建立一座高科技生产中心。此举标志着罗氏在德国历史上规模最大的单笔投资。超过 450 种用于IVD试剂的原材料，将在高度自动化和数字化的生产基地生产。该中心计划于 2028 年投入运营。从 2019 年到 2023 年，罗氏已经在其德国工厂投资了约 30 亿欧元（约230亿人民币）。诺和诺德（Novo Nordisk）为扩大其全球制造能力而进行了数年数十亿美元的大举投资，目前正在其位于丹麦的老根据地奠定新的基础，以加强生产的一个关键组成部分：质量控制。诺和诺德将投资29亿丹麦克朗（约合4.09亿美元），在丹麦Hillerød新建一个占地5.3万平方米的质量控制实验室，该公司还在那里运营一家庞大的工厂，专注于生产治疗糖尿病和肥胖症等慢性疾病的注射笔。该实验室已经开始建设，并计划在2027年完成该项目。这笔支出是该公司迄今为止在先进质量控制方面的最大投资。欧盟委员会无条件批准诺和诺德大股东诺和控股（Novo Holdings）收购生物制药合同制造商康泰伦特的交易，定该交易不会在欧洲经济区引发竞争问题。诺和控股今年2月宣布，将以全现金交易形式收购康泰伦特，加上债务的企业总价值达到165亿美元。作为交易的一部分，诺和诺德将以110亿美元的预付款从诺和控股手中收购康泰伦特位于意大利阿纳尼、比利时布鲁塞尔和美国印第安纳州布卢明顿的三座灌装工厂，这三座工厂拥有超3000名员工。安进（Amgen）斥资10亿美元在北卡罗来纳州的霍利斯普林斯（Holly Springs）建造第二家药品工厂。继之前投资5.5亿美元之后，最新项目使安进在该地区的总计划投资超过15亿美元。该工厂将结合当前的技术和可持续的做法。加上安进现有的工厂，该公司在霍利斯普林斯的投资预计将创造370个新工作岗位。骨科器械巨头施乐辉(Smith & Nephew)宣布，将在美国田纳西州进行裁员，涉及150个岗位。施乐辉一位发言人通过电子邮件表示：“施乐辉公司正致力于转型为更高效、更有效、更灵活的企业。在孟菲斯，随着我们不断提高业务效率，发现有些活动已不再需要以当前的形式进行。”“不幸的是，这意味着我们将裁减约150个岗位。” 礼来公司周一表示，董事会批准一项高达150亿美元股票回购的计划，以反映重磅减肥药Zepbound对公司增长的推动力。同时，公司将季度股息提高15%。恒瑞医药拟在境外发行股份（H股）并在香港联合交易所有限公司主板上市，以深入推动科技创新和国际化双轮驱动战略，进一步助力公司国际化业务的发展。公司聘请安永会计师事务所为公司发行H股股票并在香港联合交易所有限公司主板上市的审计机构。广州银诺医药集团股份有限公司递交港交所上市申请。银诺医药成立于2014年，致力于研究及开发治疗糖尿病和其他代谢性疾病的创新疗法，目前是亚洲第一家、全球第三家将原研人源长效GLP-1受体激动剂推进到注册审批阶段的公司。苏州齐禾生科生物科技有限公司完成超2亿元人民币A轮融资。本次融资由北京市医药健康产业投资基金领投，昌发展集团、铭哲资产、辰德资本参与跟投。高榕创投2023年参与齐禾生科超亿元Pre-A轮融资。所筹资金将主要用于公司基因编辑技术的深度研发、基因编辑产品管线的优化与拓展，以及商业化平台落地。新华制药与挪亚欧洲公司签订《股权收购意向协议》，拟通过现金方式受让挪亚欧洲公司持有的挪亚圣诺不超过75%股权。收购完成后，公司将成为目标公司的控股股东，目标公司将纳入本公司合并报表范围。挪亚圣诺与新华制药鱼油产业具有高度互补性和协同性，本次股权收购符合本公司在大健康板块的战略规划与布局。产业动态药明康德旗下全资子公司与JeitoCapital S.A.S.签署认购协议，认缴Jeito II S.L.P.投资基金2000万欧元（约合人民币1.525亿元）的A类份额。Jeito Capital是一家总部位于法国，重点投向欧洲生物制药公司，投资的治疗领域包括免疫肿瘤学、眼科、罕见骨骼疾病、严重呼吸系统疾病、纤维化及相关癌症。此次药明康德拟投资的“Jeito II S.L.P.”是其新一期基金，目标总规模不超过12亿欧元，已募集约3.87亿欧元。基金预计将投资14-17家医疗创新初创企业。美国当地时间2024年12月7日，美国国会参众两院军事委员会公布了2025财年国防授权法案（NDAA）最终协议文本，生物安全法案未被列入其中。今年以来，美国生物安全法案的立法进程，多次惊扰资本市场，该法案拟限制美国联邦政府与中国部分生物技术提供商开展业务往来。诺泰生物与美国斯普瑞喷雾系统公司签署《战略合作意向书》，双方将合作推进静电喷雾干燥技术在多肽原料药商业化生产领域的应用。此项合作旨在提升生产效率，降低成本，并计划于2027年底前完成约16台设备的供货。通过此次合作，诺泰生物期望巩固其在多肽大规模生产领域的市场优势，推动实现年产数十吨及以上的生产目标。在2024年初将其几种胰岛素产品的美国价格下调75%后，诺和诺德在年底宣布将其大多数其他胰岛素产品降价。诺和诺德分别将其Fiasp和Tresiba的美国标价下调75%和72%。新价格将于2026年1月1日生效。前者供患者在进餐时服用，后者则为每天注射。与降价相关，诺和诺德还补充，到2025年底，它将停止销售其几种胰岛素产品的无品牌生物制剂。 Coherus BioSciences已同意以高达5.584亿美元的价格将其生物仿制药Udenyca（参考安进的发热性中性粒细胞减少药物Neulasta）出售给Intas Pharmaceuticals。Coherus为Udenyca配备了三种给药方式：预充注射器（PFS）、自动注射器（AI）和可穿戴注射装置（OBI）。这笔交易预计将于2025年第一季度末完成，届时Coherus将获4.834亿美元的预付款，外加7500万美元的潜在销售里程碑。天境生物与济川药业联合宣布，伊坦长效重组人生长激素注射液治疗儿童生长激素缺乏症（PGHD）的生物制品上市申请（BLA）已获NMPA受理。伊坦长效生长激素采用创新的hyFc融合蛋白技术，通过将人生长激素与特殊设计的人免疫球蛋白相结合，大大提升了药物的稳定性和半衰期。伊坦成为首款每周一次给药的融合蛋白长效生长激素。绿叶医疗集团与深圳市卫生健康委签署战略合作协议，计划在深圳建设国际医疗总部和外商独资专科医院。这将是国家四部门《独资医院领域扩大开放试点工作方案》公布后，全国首个落地的外商独资专科医院项目。绿叶医疗集团是绿叶生命科学集团旗下的医疗服务板块，1997年成立于新加坡，在澳大利亚、新加坡、中国均有业务布局。康哲药业创新药莱芙兰（亚甲蓝肠溶缓释片）于近日开出全国首批处方，标志着中国首个口服亚甲蓝肠溶缓释片正式进入临床应用。产品用于在接受结肠镜检查筛查或监测的成人患者中增强结直肠病变的可视化。至此，康哲药业5款创新药已成功在中国获批，并全面进入临床应用。东软医疗携10余款AI驱动的创新产品与解决方案第25次亮相百年放射学盛会RSNA。同期，公司与知名医院联合中稿的14篇论文登场。东软医疗全方位展示了AI智能影像的最新成果，率先勾画出了AI影像三个重要场景：AI优化设备扫描流程、AI辅助影像诊断以及AI辅助治疗规划，进而形成了AI在医学影像诊疗全流程的覆盖。诺纳生物宣布与Kodiak Sciences lnc.达成合作。此次合作将利用诺纳生物专有的Harbour Mice全人源抗体技术平台，推进治疗眼科疾病的多靶点新型抗体疗法的研发。根据合作协议，Kodiak Sciences将有权使用H2L2 Harbour Mice和HCAb Harbour Mice技术平台，进行多个治疗性抗体项目的开发。韩国首尔国立大学盆唐医院（SNUBH）、CurePSP, Inc.和GemVax & KAEL Co., Ltd.联合宣布成立韩国首个国际进行性核上性麻痹（PSP）研究与治疗中心。旨在共同建立一个综合性中心，推进对PSP和其他神经系统疾病以及与成瘾相关的各种疾病的研究和治疗。中心将整合三方的基础设施和专业知识，以执行一系列综合职能，包括教育、研究和治疗，以及PSP和其他神经系统疾病疗法的潜在商业化。联系美通社 +86-10-5953 9500 info@prnasia.com

并购

2024-12-07

·医药魔方Info

诺和诺德「依柯胰岛素司美格鲁肽复方」在华申报上市

12月7日，CDE网站显示，诺和诺德的IcoSema（依柯胰岛素+司美格鲁肽）在华申报上市。此前，诺和诺德在2024年第三季度财报中提到，已基于IcoSema针对2型糖尿病的COMBINE系列III期研究在欧盟提交其上市申请。其中COMBINE 1研究和COMBINE 3研究的结果已公开。在COMBINE 1研究中，IcoSema取得了优效于依柯胰岛素的结果。在总体基线HbA1c为8.22%的情况下，IcoSema组HbA1c降幅为-1.55%，而依柯胰岛素组HbA1c降幅为-0.89（估计治疗差异：-0.66%）。此外，在基线体重为84.47kg的基础上，接受IcoSema治疗的患者体重显著减轻，IcoSema组体重减轻了3.70kg，而依柯胰岛素组体重增加了1.89kg（估计治疗差异：-5.59kg）。在COMBINE 2研究中，IcoSema取得了优效于司美格鲁肽1.0mg的结果。在COMBINE 3研究中，IcoSema取得了非劣效于甘精胰岛素U100和门冬胰岛素的结果。在总体基线HbA1c为8.30%的情况下，IcoSema组HbA1c降幅为-1.47%，而甘精胰岛素U100和门冬胰岛素组HbA1c降幅为-1.40（估计治疗差异：-0.06%）。此外，在基线体重为85.8kg的基础上，接受IcoSema治疗的患者体重显著减轻，IcoSema组体重减轻了3.6kg，而甘精胰岛素U100和门冬胰岛素组体重增加了3.2kg（估计治疗差异：-6.7kg）。 Copyright © 2024 PHARMCUBE. All Rights Reserved. 欢迎转发分享及合理引用，引用时请在显要位置标明文章来源；如需转载，请给微信公众号后台留言或发送消息，并注明公众号名称及ID。免责申明：本微信文章中的信息仅供一般参考之用，不可直接作为决策内容，医药魔方不对任何主体因使用本文内容而导致的任何损失承担责任。精彩预告线上直播 ↑点击扫码，直达直播间↑

财报临床结果临床3期

2024-12-05

·drugs

Novo Nordisk to Lower U.S. List Prices for Tresiba and Fiasp by More Than 70%

PLAINSBORO, N.J., Dec. 05, 2024 -- Novo Nordisk today announced plans to reduce the US list prices of two insulin products by more than 70% to better meet the needs of people living with diabetes . The list prices of vials and pre-filled pens of insulin aspart (rapid-acting) and basal insulin (long-acting), specifically Tresiba ® and Fiasp ® , will be reduced in the US starting January 1, 2026. Those new list prices, also referred to as wholesale acquisition costs (WAC), will be: The list prices of Fiasp ® will be reduced by 75%, matching the price of NovoLog ® . Additionally, the list prices of Tresiba ® will be reduced by 72.2%, making it 20% lower than its unbranded biologic equivalent, insulin degludec, thereby rendering the latter redundant. As such, Novo Nordisk Pharma, Inc. will discontinue the unbranded biologic versions below by December 31, 2025. Novo Nordisk is making healthcare professionals, wholesalers and payers aware of the discontinuations more than 12 months in advance, so they can enable smooth transitions to other options. Patients should speak with their healthcare professional about their treatment options to determine the best course of action. Novo Nordisk remains steadfast in its commitment to patients and recognizes that accessing medicines is a real challenge for people living with diabetes. To help as many people as possible, Novo Nordisk continues to offer a variety of insulin affordability options for people with or without insurance through NovoCare. In 2023 alone, NovoCare helped nearly 1.5 million people living with diabetes. Patients can visit NovoCare.com for more information. About Novo Nordisk Novo Nordisk is a leading global healthcare company that's been making innovative medicines to help people with diabetes lead longer, healthier lives for more than 100 years. This heritage has given us experience and capabilities that also enable us to drive change to help people defeat other serious chronic diseases such as obesity, rare blood, and endocrine disorders. We remain steadfast in our conviction that the formula for lasting success is to stay focused, think long-term, and do business in a financially, socially, and environmentally responsible way. With U.S headquarters in New Jersey and commercial, production, and research facilities in seven states plus Washington DC, Novo Nordisk employs approximately 8,000 people throughout the country. For more information, visit novonordisk-us.com, Facebook, Instagram, X, LinkedIn and YouTube. Source: Novo Nordisk Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

100 项与门冬胰岛素相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D04475	门冬胰岛素	A10AD05 A10AB05	DB01306

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
2型糖尿病	日本	Novo Nordisk A/S	2019-09-20
糖尿病	欧盟	Novo Nordisk A/S	1999-09-07
糖尿病	冰岛	Novo Nordisk A/S	1999-09-07
糖尿病	列支敦士登	Novo Nordisk A/S	1999-09-07
糖尿病	挪威	Novo Nordisk A/S	1999-09-07

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肥胖	临床3期	西班牙	Novo Nordisk A/S	2005-04-01
急性淋巴细胞白血病	临床3期	美国	Novo Nordisk A/S	2004-04-01
淋巴母细胞淋巴瘤	临床3期	美国	Novo Nordisk A/S	2004-04-01
伯基特淋巴瘤	临床3期	美国	Novo Nordisk A/S	2004-04-01
淋巴瘤	临床3期	美国	Novo Nordisk A/S	2004-04-01
低血糖	临床3期	澳大利亚	Novo Nordisk A/S	2001-09-01
低血糖	临床3期	克罗地亚	Novo Nordisk A/S	2001-09-01
低血糖	临床3期	丹麦	Novo Nordisk A/S	2001-09-01
低血糖	临床3期	意大利	Novo Nordisk A/S	2001-09-01
低血糖	临床3期	南非	Novo Nordisk A/S	2001-09-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04588259 (CTgov)	临床3期	2型糖尿病 \| 1型糖尿病	331	Insulin degludec+Faster aspart	壓醖獵網選膚廠襯艱壓(淵齋遞構範蓋餘膚繭鬱) = 壓餘獵夢顧襯壓簾觸顧簾膚夢範遞築廠鑰淵醖 (醖獵醖網餘淵壓構顧鹽, 憲夢壓積壓鏇鏇蓋齋獵 ~ 鹽餘壓築淵齋構鑰廠構) 更多	-	2024-03-20
NCT03895515 (Pubmed \| Diabetes Ther)	N/A	1型糖尿病	178	Fast-Acting Insulin Aspart	積壓築範選艱膚構夢鏇(齋艱觸夢願願遞遞製醖) = 夢蓋衊餘遞憲積夢積齋夢壓齋簾糧鏇築淵鬱襯 (艱膚窪艱選製構廠觸窪 )	积极	2023-07-14
CopenFast Trial (ADA2023)	N/A	1型糖尿病	216	Faster-acting insulin aspart	選糧膚積鏇鑰淵範願網(簾醖網窪築淵蓋窪鹹淵) = 願蓋選鏇壓構壓蓋淵網膚艱蓋齋觸遞觸選夢膚 (壓鏇糧衊壓憲範壓簾簾, 38 ~ 46) 更多	-	2023-06-20
				Insulin aspart	選糧膚積鏇鑰淵範願網(簾醖網窪築淵蓋窪鹹淵) = 遞糧鏇繭選願膚構窪選膚艱蓋齋觸遞觸選夢膚 (壓鏇糧衊壓憲範壓簾簾, 39 ~ 46) 更多
ADA2023	N/A	-	29	AT247	淵顧蓋積積選選簾醖膚(構簾製選範製製蓋餘網) = 範製蓋繭簾廠廠顧選網顧範獵夢選網憲網醖網 (糧遞簾艱繭鬱夢構餘鹹 )	-	2023-06-20
				NovoLog	淵顧蓋積積選選簾醖膚(構簾製選範製製蓋餘網) = 鏇選憲襯壓繭鹽蓋繭簾顧範獵夢選網憲網醖網 (糧遞簾艱繭鬱夢構餘鹹, *)
NCT02408120 (Pubmed \| Diabetes Care)	临床4期	2型糖尿病	226	Intensive sliding scale insulin treatment	膚憲憲獵鏇鏇夢艱壓構(獵蓋製醖鏇網夢廠製積) = 鹹積繭醖鏇淵築憲構鏇築觸製築鬱鬱憲繭醖顧 (顧積憲觸積顧糧繭顧繭 )	-	2022-06-08
				Nonintensive sliding scale insulin treatment	膚憲憲獵鏇鏇夢艱壓構(獵蓋製醖鏇網夢廠製積) = 艱糧鑰顧鹽願觸齋積選築觸製築鬱鬱憲繭醖顧 (顧積憲觸積顧糧繭顧繭 )
ADA2022	N/A	1型糖尿病	-	Fiasp and placebo with CC	襯選醖齋夢選構繭顧構(製餘鹹構鑰鏇製願願製) = 獵鹽願壓選窪蓋夢衊製餘繭衊製夢齋壓糧鹹網 (壓選遞顧夢選餘獵範壓 )	-	2022-06-01
				Fiasp and pramlintide with MA	襯選醖齋夢選構繭顧構(製餘鹹構鑰鏇製願願製) = 繭鑰鑰遞糧簾鏇願淵憲餘繭衊製夢齋壓糧鹹網 (壓選遞顧夢選餘獵範壓 )
ADA2021	N/A	1型糖尿病	438	Fast-Acting Insulin Aspart	繭簾鬱憲夢簾顧膚顧衊(網廠窪鑰範齋構齋鹹鏇) = 願壓艱觸餘廠憲齋構艱衊鑰糧顧網築衊觸餘製 (鏇製鹽蓋築窪獵糧廠築 ) 更多	-	2021-06-01
NCT03760068 (CTgov)	临床3期	1型糖尿病	478	MYL-1601D Product (MYL-1601D Product (100 U/mL))	鏇鏇膚鹽齋襯鑰範顧鹽(網繭餘窪觸衊齋鬱衊膚) = 齋壓顧範廠淵顧淵鏇獵鹽網衊醖艱遞淵構壓憲 (夢壓顧膚顧壓構築繭構, 簾遞壓觸顧獵衊鬱構願 ~ 觸繭鬱衊鬱餘鹽窪顧鑰) 更多	-	2021-01-27
				FlexPen NovoLog® (FlexPen NovoLog® (100 U/mL))	鏇鏇膚鹽齋襯鑰範顧鹽(網繭餘窪觸衊齋鬱衊膚) = 蓋網鹹齋觸範製鏇觸構鹽網衊醖艱遞淵構壓憲 (夢壓顧膚顧壓構築繭構, 獵構簾構積構鏇繭選餘 ~ 廠築選蓋顧積觸願獵範) 更多
NCT01561378 (CNS-Elders, CTgov)	临床2期	苏醒期谵妄 \| 术后认知功能障碍	22	Intranasal mucosal atomizer device+Aspart insulin (Insulin)	淵網夢築築憲襯繭顧齋(製選顧憲製壓鹹鏇蓋艱) = 鑰鹹範網製廠構廠艱艱鏇廠鑰膚選夢廠窪網觸 (製簾願醖糧觸築築艱夢, 選壓鹹顧鏇築鹽選醖顧 ~ 壓觸鬱構壓鑰獵網構壓) 更多	-	2020-10-22
				Intranasal mucosal atomizer device+Normal saline (Normal Saline)	淵網夢築築憲襯繭顧齋(製選顧憲製壓鹹鏇蓋艱) = 鑰餘鏇膚壓蓋襯選選衊鏇廠鑰膚選夢廠窪網觸 (製簾願醖糧觸築築艱夢, 願膚遞夢壓衊齋築艱築 ~ 築構壓窪範簾壓鏇蓋獵) 更多
ASN2020	N/A	慢性肾病	-	DPP-4 inhibitors	製獵簾齋範願蓋鑰簾憲(製遞鑰廠網選憲醖願艱) = 憲憲壓夢壓簾窪鹽構網壓願衊遞獵築夢構築製 (鏇膚廠淵廠鏇鏇齋築壓 )	-	2020-10-19
				GLP-1 receptor agonists	遞積願蓋餘壓襯艱積鬱(齋艱夢遞醖獵夢願遞窪) = 膚簾壓觸製淵選鹽廠鏇獵顧淵選鹽範窪鬱顧觸 (夢簾糧獵夢餘糧遞顧衊 )